-
Mashup Score: 2
Here is a look back on all the FDA happenings from the month of January 2025.
Source: www.targetedonc.comCategories: General Medicine News, Oncologists1Tweet
-
Mashup Score: 0FDA Updates in Urology: January 2025 - 3 day(s) ago
A recap of the FDA submissions and regulatory decisions in urology from January 2025.
Source: www.urologytimes.comCategories: General Medicine News, UrologyTweet-
Stay up to date on key #FDA news with Urology Times’ monthly regulatory update! Learn about last month's key developments here: https://t.co/4RFM4azTuJ
-
-
Mashup Score: 2FDA Fast Tracks Abenacianine for Lung Cancer Surgery - 4 day(s) ago
Abenacianine, a tumor-targeted fluorescent imaging agent, received fast track designation from the FDA after demonstrating its safety and efficacy in visualizing lung tumors in a phase 2 study.
Source: www.targetedonc.comCategories: General Medicine News, Oncologists1Tweet-
The #FDA has granted fast track designation to abenacianine for injection (VGT-309) for use as an adjunct during surgery. https://t.co/aVVIdhEukC
-
-
Mashup Score: 4
“The biggest thing that I took away from using the device is that it allowed me to do the procedure by myself, without an assistant,” says Matthew J. Mutter, MD.
Source: www.urologytimes.comCategories: General Medicine News, UrologyTweet-
Signati Medical has filed an application with the #FDA for market clearance of its Separo sealing system for vasectomy. In this interview, Matthew Mutter, MD, highlights the data supporting the application and his experience with the device. @MuttaJ https://t.co/LMvPHiezwi
-
-
Mashup Score: 4
“The biggest thing that I took away from using the device is that it allowed me to do the procedure by myself, without an assistant,” says Matthew J. Mutter, MD.
Source: www.urologytimes.comCategories: General Medicine News, UrologyTweet-
Signati Medical has filed an application with the #FDA for market clearance of its Separo sealing system for vasectomy. In this interview, Matthew Mutter, MD, highlights the data supporting the application and his experience with the device. @MuttaJ https://t.co/LMvPHiezwi
-
-
Mashup Score: 3FDA Grants Belzutifan Priority Review For Advanced Pheochromocytoma and Paraganglioma - 10 day(s) ago
The FDA granted priority review for belzutifan for treating advanced pheochromocytoma and paraganglioma, with a PDUFA date set for May 26, 2025.
Source: www.targetedonc.comCategories: General Medicine News, Onc News and JournalsTweet-
The #FDA granted priority review to a supplemental new drug application seeking the approval of belzutifan for the treatment of patients aged 12+ with advanced, unresectable, or metastatic pheochromocytoma and paraganglioma. https://t.co/TuPjUzAC6k
-
-
Mashup Score: 3
Check out the key regulatory decisions set to happen early this year.
Source: www.urologytimes.comCategories: General Medicine News, UrologyTweet-
🚨 Big news on the horizon for urology in 2025! Take a look through the key #FDA decisions set to happen in the first half of this year. https://t.co/FqICuojpxo
-
-
Mashup Score: 1FDA Approves T-DXd in HR+, HER2-Low/Ultralow Breast Cancer - 11 day(s) ago
The FDA approved trastuzumab deruxtecan for adult patients with unresectable or metastatic HER2-low or HER2-ultralow breast cancer, based on phase 3 DESTINY-Breast06 trial results.
Source: www.targetedonc.comCategories: General Medicine News, Oncologists1Tweet-
The #FDA has approved T-DXd for treating adult patients with unresectable or metastatic, HR+, HER2-low or HER2-ultralow breast cancer, as determined by an FDA-approved test, that has progressed on 1 or more endocrine therapies in the metastatic setting. https://t.co/lEfQoON7VW https://t.co/p71LfSPqH8
-
-
Mashup Score: 4
Pending phase 3 trial results, a biologics license application will be submitted for the KRAS-targeting cancer vaccine ELI-002.
Source: www.targetedonc.comCategories: General Medicine News, Oncologists1Tweet-
#FDA Supports Registrational Strategy for ELI-002 in KRAS-Driven Cancers https://t.co/LYvStB2esU
-
-
Mashup Score: 3
The combination of treosulfan and fludarabine as a preparative regimen for allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia or myelodysplastic syndromes has been approved by the FDA.
Source: www.targetedonc.comCategories: General Medicine News, Oncologists1Tweet-
#FDA Greenlights Treosulfan/Fludarabine Combo for AlloHSCT in AML and MDS https://t.co/9wxtimqYB1
-
In January 2025, the #FDA granted several key approvals in oncology. Here is a look back on all the FDA happenings from the month. https://t.co/w5h6gRgHzW